Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Genoa Pharma, McMaster U In IPF Research Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Genoa Pharma, McMaster U In IPF Research Pact

To explore inhaled delivery for pulmonary fibrosis drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genoa Pharmaceuticals and Dr. Martin Kolb and researchers at McMaster University have entered into a collaboration to characterize the in vivo advantages and potential clinical impact of Genoa’s lead program, inhaled GP-101 (aerosol pirfenidone) for the treatment of IPF. The research combines Genoa’s aerosol drug delivery expertise with McMaster’s expertise in exploring mechanisms of pulmonary fibrosis.
 
“Genoa is very excited about the opportunity to collaborate with Dr. Kolb and McMaster University to better understand how inhaled GP-101 may benefit IPF patients,” said Mark Surber, Ph.D., Genoa’s founder, president and chief scientific officer. “Genoa is committed to establishing academic relationships with leading institutions to further advance its efforts to develop novel treatments for IPF.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics